Atossa Therapeutics Approves 15:1 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Atossa Therapeutics announced a 15:1 reverse stock split, effective February 2, 2026, a strategic move to maintain its Nasdaq listing amidst recent positive drug development news.

check_boxKey Events

• Reverse Stock Split Approved

  The Board of Directors approved a 15:1 reverse stock split of the common stock, following stockholder approval at a Special Meeting on January 20, 2026.

• Effective Date Set

  The reverse stock split will become effective at 12:01 a.m. Eastern Time on February 2, 2026, with split-adjusted trading commencing the same day.

• Nasdaq Listing Compliance

  The action is intended to increase the per-share trading price, likely to ensure compliance with Nasdaq's minimum bid price requirement.

• Fractional Shares Handled by Cash Payment

  No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the closing price on January 30, 2026.

auto_awesomeAnalysis

Atossa Therapeutics' Board of Directors approved a 15:1 reverse stock split, effective February 2, 2026, following stockholder approval. This action is typically undertaken by companies whose stock price has fallen below exchange minimums, in this case, likely to maintain compliance with Nasdaq's minimum bid price requirement. While reverse stock splits do not change a company's fundamental value, they are often viewed negatively by the market as they reflect past stock underperformance. However, for a life sciences company like Atossa, maintaining a Nasdaq listing is crucial for investor visibility, liquidity, and access to capital for its ongoing drug development programs. This move follows recent positive news, including an FDA "Study May Proceed" letter for an investigational new drug application and a strong cash position, suggesting the company is taking necessary steps to ensure its long-term market presence and funding capabilities.